|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Multiple Sclerosis - Disease-modifying Efficacy and Side Effects Guide Treatment Choice
Datamonitor, Dec 2006, Pages: 175
The disease-modifying drugs are considered by physicians to represent a significant advance for the management of MS. However, none is fully effective and there are problems with regards to side effects, dosing regimens and cost. Tysabri, a novel once-monthly drug is expected to be an improvement in terms of efficacy; however, there remains a concern over side effects and long-term safety.
Scope of this title:
- Overview of epidemiology, presentation, referral and diagnostic assessment in MS
- Breakdown of first-line to fourth-line treatment regimens and treatment choice according to disease category
- Influences on treatment choice and perception of current drug therapies
- Evaluation of unmet needs and future outlook
Highlights of this title:
- Multiple sclerosis affects less than 1% of the population in the US and Europe. Despite the high level of general awareness of the disease, neurologists estimate less than half of individuals present at the time they suffer from first symptoms and it can take more than one year to receive an accurate diagnosis.
- Numerous strategies, including switching to an alternative interferon beta, are adopted as second-line therapy. Although not favored by opinion leaders or US neurologists, combining two disease-modifying drugs is popular in the 5EU markets. Given the willingness of neurologists to try this strategy, further trials are required.
- Tysabri is perceived by neurologists as offering a clear improvement in terms of disease-modifying efficacy. However, a lack of long-term safety data will ensure for the moment it remains positioned as a last-line therapy for relapse-remitting patients who have failed first- and second-line treatment with interferon beta or glatiramer acetate.
Reasons to order your copy:
- Target prescribers more effectively, through an understanding of prescribing behavior and its influences
- Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products
- Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies
Customers who bought this item also bought
Strategic Perspectives 2001: Antidepressant Treatment Strategies - Efficacy Drives Psychiatrist Drug Choice
Prostate Cancer Insight - Profiting From Changing Treatment Patterns
Metabolic Syndrome - Multiple Definitions Complicate Treatment
U.S. Autoimmune Disorders Markets for Biologics
Stakeholder Insight: Atrial Fibrillation - Limited Efficacy and Poor Safety Lead to Bleak Outlook
Trends and Developments in the European Urinary Incontinence
Commercial Perspectives: Multiple Sclerosis - How to Find Opportunities in an Unremitting Market
Stakeholder Insight: Alzheimers Disease - Prescribing Trends Indicate That Neurologists Are Not Adhering to Guidelines
|
|
|
|
